瑞戈非尼在转移性结直肠癌治疗中的研究进展  

Research progress of regorafenib in the treatment of metastatic colorectal cancer

作　　者：靳可欣 魏孝礼[1] 白玉贤[1] JIN Kexin;WEI Xiaoli;BAI Yuxian(The Second Department of Internal Medicine,the Affiliated Cancer Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院内二科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2024年第22期4407-4412,共6页Journal of Modern Oncology

摘　　要：2022年全球癌症统计数据显示,结直肠癌的发病率和死亡率均位居前列。大多数患者确诊时已为中晚期,失去手术机会。分子分型指导下进行个体化、精准化治疗是目前转移性肠癌的治疗策略。血管生成在肿瘤细胞增殖、血管重塑、细胞侵袭和转移中起到必不可少的作用。近年来肠癌的靶向治疗研究取得众多突破性进展。瑞戈非尼作为新型小分子靶向药物,可同时靶向作用于多个受体位点,在晚期肠癌的治疗中疗效显著,已获批作为转移性肠癌三线标准治疗方案。该综述主要盘点瑞戈非尼在转移性结直肠癌中的国内外最新研究进展,以帮助其进一步获益并应用于临床。According to global cancer statistics 2022,the incidence and mortality of colorectal cancer are among the highest.Most patients are diagnosed in the middle and late stages and lose the chance of surgery.Individualized and precise treatment under the guidance of molecular typing is the current treatment strategy for metastatic colorectal cancer.Angiogenesis plays an essential role in tumor cell proliferation,vascular remodeling,cell invasion and metastasis.In recent years,many breakthroughs have been made in targeted therapy of colorectal cancer.As a new small-molecule targeting drug,regorafenib can simultaneously target multiple receptor sites,and has a significant effect in the treatment of advanced colorectal cancer,and has been approved as a third-line standard treatment for metastatic colorectal cancer.This article mainly reviews the latest research progress of regorafenib in metastatic colorectal cancer,in order to further benefit and clinical application of regorafenib.

关 键 词：转移性结直肠癌 瑞戈非尼 靶向治疗 联合治疗 抗血管生成 

分 类 号：R735.3[医药卫生—肿瘤]